Frauenshuh Cancer Center

567 XTX301, a tumor-activated Interleukin-12 (IL-12), demonstrated IL-12 pharmacology in patients with advanced solid tumors: pharmacodynamic data from first-in-human phase 1 study (NCT05684965)

Douglas R. Adkins, William H. Bradley, Richard Wu, Martín Gutiérrez et autres

Background XTX301 is a tumor-activated IL-12 designed to potently stimulate anti-tumor immunity and reprogram the tumor microenvironment (TME) of poorly immunogenic ‘cold’ tumors towards an inflamed or ‘hot’ state. The tumor-activated design enables localized activity of XTX301 in the TME, thereby widening …

us (code pays fourni par la source)

PATH-94. Use of tovorafenib for BRAF mutant or altered CNS tumors in adults: a single institution case series

Andrew E. Williams, Sydney Schultz, Joon H. Uhm, Michael W. Ruff et autres

Abstract BACKGROUND Tovorafenib is a type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor approved by the FDA in 2024 for relapsing or chemotherapy-refractory pediatric low-grade gliomas with mutations or alterations in the gene BRAF. There is potential for the use of this …

us (code pays fourni par la source)

List of contributors

Rolla Abu-Arja, Jenny Adamski, Manish K. Aghi, Manmeet Singh Ahluwalia et autres

us, gb, il, ca, de, ph, ge (code pays fourni par la source)

682 Ongoing phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical safety update and renal cell carcinoma (RCC) efficacy analysis

David Sommerhalder, Kurt Demel, Marcus Smith Noel, Hamid Emamekhoo et autres

Background NDI-101150 is a potent, selective, oral inhibitor of hematopoietic progenitor kinase 1 (HPK1), with an immunotherapy mechanism distinct from checkpoint inhibitors. NDI-101150 activates the anti-tumor activity of T-cells, B-cells, and dendritic cells, even under immunosuppressive conditions. Methods This first-in-human, multicenter, open-label, …

us (code pays fourni par la source)

83 Tumor immune microenvironment characterization from pre- and post-dose tumors collected from a phase 1/2 study of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor

Scott R. Daigle, GiNell Elliott, Scott Boiko, David Sommerhalder et autres

Background NDI-101150, an oral, selective, small molecule inhibitor of HPK1, is being studied as monotherapy and in combination with pembrolizumab. HPK1, a MAP4K family kinase, negatively regulates T-, B-, and dendritic cells, with preclinical studies showing immune reactivation following treatment.1 In an …

us (code pays fourni par la source)

Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.

Marcus Smith Noel, Kurt C. Demel, Bhaskar Srivastava, Scott R. Daigle et autres

3083 Background: NDI-101150 is a potent, selective, oral inhibitor of hematopoietic progenitor kinase 1 (HPK1), with a different immunotherapy mechanism to other checkpoint inhibitors. NDI-101150 reactivates anti-tumor activity of T-cells, B-cells and dendritic cells (DCs), even under immunosuppressive conditions. Methods: Safety and …

us (code pays fourni par la source)

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Mitchell R. Smith, Opeyemi A. Jegede, Peter Martin, Brian G. Till et autres

ABSTRACT: Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial …

us, ca (code pays fourni par la source)

Bisphenol A exposures and hormone concentrations in a cohort of women receiving aromatase inhibitor therapy for breast cancer.

Kim Robien, Mark N. Kirstein, Pamala A. Pawloski, Alice Shapiro

e12535 Background: Bisphenol A (BPA), a widely used chemical in plastics production, has been shown to have estrogenic activity, although it is unclear whether BPA exposure alters effectiveness of aromatase inhibitor (AI) treatment among women with breast cancer. In vitro studies have …

us (code pays fourni par la source)

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Mitchell R. Smith, Opeyemi A. Jegede, Peter Martin, Brian G. Till et autres

7503 Background: Optimal initial therapy for mantle cell lymphoma (MCL) remains uncertain. The randomized phase 2 NCTN trial E1411 tested if progression-free survival (PFS) is prolonged by addition of bortezomib (V) (1.6 mg/m2 SC/IV days 1, 8) to bendamustine-rituximab (BVR vs BR) …

us (code pays fourni par la source)

Monitoring Rates of Malnutrition Risk in Outpatient Cancer Centers Utilizing the Malnutrition Screening Tool Embedded into the Electronic Health Record

Elaine B. Trujillo, Alice Shapiro, Natalie Stephens, Sarah J. Johnson et autres

BACKGROUND: The risk of malnutrition in patients with cancer is well documented. However, screening to identify patients at risk in ambulatory cancer centers is not standardized nor uniform. The 2-question Malnutrition Screening Tool (MST) is validated in the ambulatory oncology setting and …

us (code pays fourni par la source)

Comprehension and personal value of negative non‐diagnostic genetic panel testing

Christin Hoell, Sharon Aufox, Nora Nashawaty, Melanie F. Myers et autres

Increasing interest and pursuit of genetic testing by the general public have raised concerns about their understanding and use of their results. While most research has focused on individuals receiving positive genetic test results, there have been limited investigations assessing the understanding …

us (code pays fourni par la source)

A Comparison of Three Music Therapy Introduction Dialogues on Acceptance of Music Therapy Services by Patients in an Outpatient Cancer Center

Leanne Kathleen Barck, Dawn M. Miller

Abstract Music therapy is not often well understood by patients with cancer; therefore, patients may be initially hesitant to accept music therapy services. The purpose of this study was to compare the effectiveness of three different scripts (described from here on as …

us (code pays fourni par la source)